PACS Group, Inc. (PACS) P/E Ratio History
Premium ValuationTrading at 29.3x vs 5Y avg 21.9x · 90th percentile · Premium to historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, PACS Group, Inc. (PACS) trades at a price-to-earnings ratio of 29.3x, with a stock price of $49.60 and trailing twelve-month earnings per share of $1.69.
The current P/E is 34% above its 5-year average of 21.9x. Over the past five years, PACS's P/E has ranged from a low of 13.2x to a high of 32.5x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, PACS trades at a 19% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, PACS commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PACS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PACS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PACS P/E vs Peers
Post-Acute & Senior Care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 26.9 | 1.95 | +14% | |
| $3B | 29.1 | 1.26 | +17% | |
| $2B | 20.8 | 1.03 | +23%Best | |
| $7B | 24.6 | - | -7% | |
| $358B | 22.4 | - | -15% | |
| $52B | 42.4 | - | -1% | |
| $107B | 9.8 | - | -62% | |
| $2B | 38.8 | - | -84% | |
| $24B | 7.9Lowest | 0.24Best | -53% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PACS Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $41.55 | $1.72 | 24.2x | +11% |
| FY2026 Q2 | - | $42.64 | $1.67 | 25.5x | +17% |
| FY2026 Q1 | - | $32.12 | $1.51 | 21.3x | -3% |
| FY2025 Q4 | Dec 31 2025 | $38.39 | $1.18 | 32.5x | +49% |
| FY2025 Q3 | - | $13.73 | $1.04 | 13.2x | -40% |
| FY2025 Q2 | Jun 30 2025 | $12.92 | $0.82 | 15.8x | -28% |
| FY2025 Q1 | Mar 31 2025 | $11.24 | $0.44 | 25.7x | +18% |
| FY2024 Q4 | - | $13.11 | $0.60 | 22.0x | +0% |
| FY2024 Q3 | Sep 30 2024 | $39.97 | $1.75 | 22.9x | +5% |
| FY2024 Q2 | Jun 30 2024 | $29.50 | $1.90 | 15.6x | -29% |
Average P/E for displayed period: 21.9x
PACS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PACS — Frequently Asked Questions
Quick answers to the most common questions about buying PACS stock.
What is PACS's P/E ratio?
PACS Group, Inc. (PACS) trailing twelve-month P/E ratio is 29.3x, based on TTM diluted EPS of $1.69. The 5-year average P/E is 21.9x and the historical range spans 13.2x to 32.5x.
Is PACS stock overvalued or undervalued?
PACS trades at 29.3x P/E, above its 5-year average of 21.9x. The 90th percentile ranking within the 13.2x–32.5x historical range indicates a premium to historical valuation.
Is PACS stock expensive?
Yes, PACS is expensive relative to its own history. The current P/E of 29.3x is above the 5-year average of 21.9x and also above the Healthcare sector median of 24.6x. The stock sits at the 90th percentile of its 5-year valuation range.
What is PACS's historical P/E range?
Over the past 5 years, PACS's P/E ratio has ranged from 13.2x to 32.5x, with a median of 22.9x and an average of 21.9x. The current P/E of 29.3x places the stock at the 90th percentile of this range. Full historical data spans 2024–2026.
How does PACS's P/E compare to the S&P 500?
PACS trades at 29.3x P/E versus the S&P 500 median of 21.8x. The 34% premium to the market typically reflects higher expected earnings growth or quality.
How does PACS's valuation compare to Healthcare peers?
PACS Group, Inc. P/E of 29.3x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PACS's PEG ratio?
PACS PEG ratio is N/A, based on a P/E of 29.3x and EPS growth of 221.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PACS's earnings yield?
PACS earnings yield is 3.41%, the inverse of its 29.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.